You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
Aug
2024
Publication half-yearly financial statements
25
Nov 24
Analysts’ Conference
Nov
Press Release – quarterly statement (call-date Q3)
12
Jun 24
Annual General Meeting
13
May 24
08
Press Release – quarterly financial report (call-date Q1)
Apr 24
Publication of Annual Report
27
Nov 23
Press Release – quarterly financial report (call-date Q3)
30
Aug 23
Jul 23
May 23
15
Apr 23
28
Nov 22
2022
Oct 22
Jun 22
21
Press Release – quarterly statement (call-date Q1)
23
May 22
18
09
Nov 21
Publication quarterly statement (call-date Q3)
Sep 21
Jun 21
Publication quarterly statement (call-date Q1)
17
May 21
10
Dec 20
16
Nov 20
11
Sep 20
22
Jun 20
May 20
Mar 20
Sep
2019
Jun 19
May 19
2018
19
Jun 18
Jun
2017
Jun 17
2015
1 July 2024
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
28 June 2024
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
13 June 2024
Formycon reports on the results of the Annual General Meeting
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
15 May 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
8 May 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
29 April 2024
Annual financial statements 2023
30 August 2023
Halbjahresabschluss 2023
Half-yearly financial statements 2023
5 May 2023
Annual financial statements 2022
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
21 August 2023
23 September 2022
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Kaufen
7 September 2022
30 August 2022
14 April 2022